Skip to content
Peptigraph home
Shop Peptides50% off*

Orforglipron Half-Life: How Long It Stays in Your System

How long Orforglipron stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medical review pendingOral small-molecule GLP-1 agonistUpdated
Half-life
approximately 29 to 49 hours
oral, in people · FDA label (Foundayo)
Dosing interval
Varies by study
as used in studies
WADA
Not listed
2026 Prohibited List
Detection window
Not found
None reported as of 2 Oct 2026

Orforglipron half-life

A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.

Orforglipron half-life by route
RouteHalf-lifeMeasured inSource
oralapproximately 29 to 49 hoursPeopleFDA label (Foundayo)
oral48.1 to 67.5 hours (day 28, 2-24 mg, healthy adults)PeopleDiabetes, obesity & metabolism 2023, PMID 37344954
oral29 to 49 hours (week 12, type 2 diabetes)PeopleDiabetes, obesity & metabolism 2023, PMID 37264711
As labelledapproximately 29 to 49 hours (oral)PeopleFDA label (Foundayo)

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of Orforglipron:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Not on the WADA Prohibited List

GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Anti-doping labs use tests built for specific substances. Whether a given test detects Orforglipron, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).

Label half-life

For the labelled tablet, the document lists the time for drug levels to halve as roughly 29 to 49 hours after an oral dose.[3]

Half-life in trials

In healthy adults, mean half-life was 24.6 to 35.3 hours after a single 0.3-6 mg dose.[4]

On Day 28 of dosing, mean half-life was 48.1 to 67.5 hours across the 2-24 mg range.[4]

In adults with type 2 diabetes, mean half-life at Week 12 ranged from 29 to 49 hours.[5]

Food and interactions

The label reports no clinically relevant food effect on exposure.[3]

A food-effect paper found half-life and median time to peak comparable between fed and fasted states.[10]

The label says strong CYP3A4 inhibitors significantly raise orforglipron exposure while inducers reduce it.[3]

Common questions

How long does orforglipron stay in your system?

The label gives an elimination half-life of approximately 29 to 49 hours.[3]

What is the half-life of Orforglipron?

Approximately 29 to 49 hours (oral); 48.1 to 67.5 hours (day 28, 2-24 mg, healthy adults) (oral), from the sources cited below.

Is Orforglipron on the WADA prohibited list?

No, it is not listed. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

More on Orforglipron

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1FDA approves first new molecular entity under National Priority Voucher program (Foundayo, orforglipron), 1 Apr 2026U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
  5. 5Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
  6. 6Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  7. 7Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
  8. 8Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
  9. 9Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
  10. 10Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024PMID 38402332Accessed 2 Oct 2026

Found an error? Report a correction.